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Summary The mechanism by which tumour necrosis factor (TNF)-a increases the susceptibility of U87-MG human glioblastoma cells to lysis by natural killer (NK) cells was studied. Treatment with TNF-a (100 units ml-) for 48 h enhanced the susceptibility of tumour cells to lysis by NK cells. Increased suscep- tibility to lysis was associated with enhanced expression of intercellular adhesion molecule I (ICAM-1) and HLA class I antigen. Antisense ICAM-I oligonucleotide inhibited lysis by NK cells of TNF-a-treated tumour cells. In contrast, acid treatment following TNF-a treatment increased lysis by NK cells. These findings indicate that TNF-a treatment of glioblastoma cells increased their susceptibility to lysis by NK cells, since ICAM-1 up-regulation would have more profound effects on NK susceptibility than would HLA class I antigen up-regulation.
Human peripheral blood monocytes include a number of
types of effector cells to which different lytic activities have
been ascribed. Natural killer (NK) cells are one such type of
cells mediating lysis. NK cells are distinct from T lym-
phocytes in that they do not rearrange or effectively tran-
scribe T-cell receptor genes and are CD3- (Lanier et al.,
1986; Biassori et al., 1988; Loh et al., 1988).
Numerous studies have shown that target cells which ex-
press a relatively low level of HLA class I antigen have
increased susceptibility to lysis by NK cells, while target cells
with a relatively high level of HLA class I antigen are less
susceptible (Ljunggren & Karre, 1985; Piontek et al., 1985;
Harel-Bellan et al., 1986; Storkus et al., 1987). On the other
hand, the results of some studies suggest that the extent of
NK cell-mediated lysis is correlated with the level of HLA
class I antigen expression only within certain ranges of ex-
pression (Storkus et al., 1989), and may be influenced by
adhesion molecules such as intercellular adhesion molecule I
(ICAM-1), which play roles in the interaction between target
cells and effector cells (Maio et al., 1991). However, the
mechanism of NK-cell lysis remains controversial.
Tumour necrosis factor (TNF)-a, a polypeptide cytokine
with a molecular weight of about 17,500 produced primarily
by macrophages, plays a role in immune defence against a
variety of pathogenic agents by virtue of its possession of a
variety of effects on cell function (Beutler & Cerami, 1987;
Old, 1987). Some of these effects may result in cell death and
tissue damage. TNF-a is directly cytocidal to certain cells and
can also enhance indirect cell killing by stimulation of other
immune functions that are themselves cytocidal (Konig et al.,
1991). In addition, TNF-a significantly enhances the expres-
sion of ICAM-1 and HLA class I antigen on treated cells
(Kuppner et al., 1990; Maio *et al., 1991). A recent study
demonstrated that TNF-ox-treated target cells are significantly
less susceptible to NK cell-mediated lysis than their untreated
counterparts (Maio et al., 1991). In contrast, in other studies
no effect of TNF-a on target cell susceptibility to NK cells
has been detected (Tomita et al., 1992).
In this study we tested the effect of TNF-a treatment of
glioblastoma cells on susceptibility to lysis by NK cells and
also attempted to determine how ICAM-1 and HLA class I
antigen modulate the susceptibility of target cells to lysis by
NK cells. We demonstrated that TNF-a-treated glioblastoma
cells have increased susceptibility to lysis by NK cells, and
that this increased susceptibility mostly depends on the in-
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creased expression of ICAM-1 molecules by target cells,
whereas HLA class I antigen expression has a protective
effect.
Materials and methods
Target tumour cells
U87-MG glioblastoma cell lines were obtained from RIKEN
Cell Bank (Saitama, Japan) and cultured in Dulbecco's
modified minimal essential medium (Nissui, Tokyo, Japan) supplemented with 10% heat-inactivated fetal calf serum
(FCS, Gibco, Grand Island, NY, USA), 4 mM glutamine, 50 Uml-' penicillin and 50 tgml-' streptomycin. Tumour
cells were harvested by overlaying the monolayer with a
solution of 0.05% trypsin and 0.53 mM EDTA (Gibco). The
following human tumour cell lines used as controls were
obtained from the American Type Culture Collection
(ATCC, Rockville, MD, USA): K562 (erythroleukaemia, NK
sensitive) and ACHN (renal cell cancer, NK resistant) (Tomita et al., 1992).
NK-cellpreparation
Peripheral blood lymphocytes in samples obtained from heal-
thy donors were isolated by Ficoll-Paque (Pharmacia Fine
Chemicals, Uppsala, Sweden) density-gradient centrifugation, and passed through nylon wool for 1 h. Non-adherent cells
were isolated by Percoll. Large granular lymphocytes were
obtained from the 2a/3a fraction of a discontinuous Percoll
density-gradient centrifugation (yield = 60-80%) (Procopio et al., 1989). After three washings with phosphate-buffered saline (PBS), these lymphocytes were cultured in RPMI-1640
supplemented with 10% heat-inactivated FCS, 1 mM sodium
pyruvate, 2 mm glutamine, 50 U ml-' penicillin and
50ytgml-' streptomycin.
TNF-am treatment and cell viability
Tumour cells were treated with TNF-a (supplied by Mochida Pharmaceuticals, Tokyo, Japan) for 48 h at concentrations
ranging between 1 and 100 units ml-'. Control cultures not
treated with TNF-cx were also established. After treatment with TNF-a, tumour cells were detached with 0.05% trypsin and 0.53 mM EDTA, washed twice and adjusted to the ap- propriate cell concentration using culture medium. On the
other hand, the cytotoxic effects of TNF-ax on tumour cells
were quantified using a modified 3-(4,5-diemthylthiazol-2-yl)-
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2,5-diphenyl tetrazolium bromide (MTT, Chemicon,
Temecula, CA, USA) colorimetric assay (Mosmann, 1983).
Target cells were seeded at I04 cells per well (0.1 ml) in
96-well flat-bottomed plates (Corning, NY, USA) and
incubated overnight at 37°C. TNF-m was then added (0.01 ml
per well) at concentrations ranging between 1 and
100unitsml-'. After a 48h period of incubation at 37°C,
0.01 ml of MTT reagent was added to each well. After
another 4 h period of incubation at 37°C, 0.1 ml of iso-
propanol with 0.04 M hydrochloric acid was added to each
well to dissolve precipitates, and absorbance was then
measured at 570 nm with an autoreader (ER-8000, Sanko
Junyaku, Tokyo, Japan) within 30 min of dissolution.
ICAM-J antisense oligonucleotide synthesis and cellular uptake
A 20-mer antisense (antisense ICAM-1) oligonucleotide (5'-
dGGACACAGATGTCTGGGCAT-3') complementary to a
sequence beginning at position 77 downstream of the ATG
initiation codon of ICAM-1 cDNA (Simmons et al., 1988)
was synthesised using methods described previously (Akella
& Hall, 1992). Oligonucleotide uptake was assayed using
methods already described (Wickstrom et al., 1988). For each
time point, 5 x I04 c.p.m. of 32P-labelled oligonucleotide was
added to 106 U87-MG cells in 0.5 ml of culture medium.
After incubation at 37°C, the cells were harvested, washed
and lysed, and percentage uptake was then determined.
between 40:1 and 5:1. The plates were then centrifuged, and
100jil of supernatant was harvested from each well and
counted in a gamma counter. Percentage cytotoxicity was
calculated as (experimental release -spontaneous release)/
(maximum release - spontaneous release) x 100. Spon-
taneous release represented the radioactivity released by 104
5'Cr-labelled target cells during a 4 h period of incubation,
and maximum release was the radioactivity released by 104
target cells lysed with 0.1% NP-40. All experiments were
performed in triplicate. Spontaneous release was as high as
15% of maximum release. Student's t-test was used to deter-
mine whether differences between group means were statis-
tically significant.
Results
Susceptibility ofTNF-a treated tumour cells to NKlysis
To determine the amount of TNF-oa necessary to induce
maximal increase in susceptibility to lysis by NK cells, we
treated U87-MG cells with various amounts of TNF-m. Fur-
thermore, to determine the time required for TNF-o-induced
increase in susceptibility to NK lysis, U87-MG cells were
treated with 100 unitsml-' TNF-x for periods of 12, 24 or
48 h prior to testing for susceptibility to NK lysis. As shown
in Figure 1, we found that treating U87-MG cells with
Acid treatment
The acid solution used was 0.2 M citric acid-disodium hy-
drogen phosphate buffer, pH 3.0, containing 1% (w/v) bovine
serum albumin prepared as previously described (Sugawara
et al., 1989). Cell pellets containing 2 x 106 U87-MG cells
were placed in 0.5 ml of the buffered solution at 4°C for
2 min. Cells were then immediately neutralised with excess
medium, washed three times and used as target cells. It has
been shown that HLA class I antigen expression is selectively
eliminated by this treatment, while the expression of other
antigens, such as HLA class II, CD3, CD4 and CD8
antigens, transferrin receptors (Sugawara et al., 1989) and
neural cell adhesion molecule (NCAM), a member of the Ig
supergene family demonstrating homology with adhesion
molecules such as ICAM-1 (Simmonds et al., 1988) (data not
shown), is not affected.
Immunofluorescence analysis
Cell pellets (1-5 x 105 cells) were treated for 30 min at 4'C
with 1 pg of monocional antibodies (MAbs). After two
washes in PBS, 4 il of fluorescein isothiocyanate-conjugated
goat anti-mouse Ig (Becton Dickinson, San Jose, CA, USA)
was added and the mixture incubated for 20 min at 4°C.
After two more washes, the cells were analysed by flow
cytometry using a FACScan (Becton Dickinson, Mountain
View, CA, USA). The MAbs used were CD54 (anti-ICAM-l;
Amac, Westbrook, ME, USA) and W6/32 (anti-HLA class I;
Dakopatts, Denmark). For determination of non-specific
binding, tumour cells were treated with normal mouse Ig
instead of MAbs. In order to inhibit the expression of
ICAM-l in U87-MG cells, 2 mM antisense ICAM-l
oligonucleotide was added every 24 h. In other experiments,
acid treatment was performed in order to eliminate the exp-
ression of HLA class I antigen.
Cytotoxicity assay
Tumour cells were labelled with 100,uCi of 5"Cr (New Eng-
land Nuclear, Boston, MA, USA) for 1 h at 37°C after
incubation with or without TNF-a for 48 h. The cells were
washed three times, centrifuged and suspended at a concen-
tration of 105 cells ml-'. Aliquots of 100jld of these target cell
suspensions were added to varying numbers of NK cells (in
1001jl) in 96-well round-bottomed plates (Corning), and the
plates were incubated for 4 h at 37'C. E/T ratios v3ried
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Figure 1 Increased susceptibility of U87-MG cells to NK cells
following TNF-a treatment in (a) a dose- or (b) a time-dependent
manner. The assays were performed with an incubation time of
4h. a, 0-0, no treatment; A-A, 1.Ounitsml-'; A-A,
10 unitsml-'; *--, 100 units ml-' TNF-a for 48 h. 0-0 ver-
sus *--, P<0.1. b, 0-0, no treatment; A-A, for 12 h;
A-A, for 24 h; 0--, for 48 h with 100 units ml- TNF-m.
0-0 versus 0*-, P<0.1. Data represent the mean ± s.d. of
three experiments.
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TNF-a at 100 units ml-' for 48 h resulted in a marked and
consistent increase in susceptibility to lysis by NK cells. In
addition, the cytotoxic effects of TNF-x on U87-MG cells
were quantified using a modified MTT assay. TNF-x at
concentrations ranging between 1 and 100 units ml-' was not
cytotoxic to tumour cells (data not shown). Without treat-
ment with TNF-a, NK-sensitive K562 cells showed the
highest susceptibility to NK lysis, while NK-resistant ACHN
cells had the lowest susceptibility (Figure 2). After treatment
with TNF-a, K562 cells showed a decreased susceptibility to
NK lysis, while ACHN cells showed no change.
Uptake ofantisense-ICAM-J oligonucleotide by U87-MG cells
In order to determine the uptake of an antisense ICAM-1
oligonucleotide by U87-MG cells, oligonucleotide labelled to
a high specific activity at its 5' end with 32p was added to
U87-MG cells in culture medium, and the percentage uptake
was determined. Nearly 6.2% of the the S'-labelled antisense
oligonucleotide was associated with the cell pellet after 8 h
(Figure 3). Total uptake continued to increase until 24 h, at
which time nearly 10% of the oligonucleotide was associated
with the cells.
Analysis ofICAM-J and HLA class I antigen on tumour cells
In order to determine the nature ofTNF-x-induced effects on
the expression of ICAM-1 and HLA class I antigen poten-
tially capable of regulating susceptibility to lysis by NK cells,
the expression of these two cell-surface molecules was
studied. As shown in Figure 4, untreated U87-MG cells
expressed ICAM-l and HLA class I antigen at a relatively
low level. U87-MG cells expressed about a 10-fold increase in
ICAM-l and about a 3-fold increase in HLA class I antigen
after TNF-o treatment. Untreated K562 cells showed a high
level of ICAM-1 expression but a very low level of HLA
class I antigen expression, while K562 cells showed about a
2-fold increase in ICAM-1 and about a 5-fold increase in
HLA class I antigen after TNF-x treatment. In addition,
untreated ACHN cells showed a very low level of ICAM-1
expression but a very high level of HLA class I antigen.
TNF-a-treated ACHN cells showed about a 3-fold increase
in ICAM-1 and about a 3-fold increase in HLA class I
antigen. Considering these data together, we suggest that the
increase in susceptibility of tumour cells to NK lysis may
mostly correlate with the up-regulation of ICAM-1 and the
decrease with up-regulation of HLA class I antigen.
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Effect ofantisense ICAM-J and acid treatment on U87-MG
cells treated with TNF-a
As shown in Figure 5, U87-MG cells treated with TNF-x
and antisense ICAM-1 oligonucleotide had no detectable
ICAM-1 on their cell surface. Moreover, acid treatment fol-
lowing TNF-a treatment drastically reduced the expression of
HLA class I antigen on the cell surface, but did not affect
cell-surface ICAM-1 expression. Therefore, the expressions of
ICAM-1 and HLA class I antigen were selectively eliminated
by antisense ICAM-l and acid treatment respectively. In
addition, the peaks shown in Figure 4 (3) and Figure Sa (2
and 4) were kinked. This result may indicate that TNF--
induces a small subpopulation of U87-MG cells which ex-
press very high levels of ICAM-1.
Effect ofICAM-I and HLA class Iantigen on NK lysis of
U87-MG cells treated with TNF-x
First, U87-MG cells were treated with TNF-a
(100 units ml-) for 48 h, and their susceptibility to lysis by
NK cells was determined by 51Cr-release assays. After treat-
ment with TNF-o, U87-MG cells had increased susceptibility
to lysis by NK cells (P<0.1) (Figure 6). In order to deter-
mine whether the increased susceptibility to lysis by NK cells
was a consequence of the increased expression of ICAM-1
and HLA class I antigen on TNF-a-treated U87-MG cells,
we selectively inhibited the expression of these molecules
using either antisense ICAM-1 or acid treatment. Treatment
with antisense ICAM-1 resulted in significant inhibition of
NK-cell-mediated lysis of TNF-a-treated U87-MG cells at
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Figure 3 Uptake of antisense ICAM- I oligonucleotide by U87-
MG cells. 5'-'_P-labelled antisense (5 x IO0 c.p.m.) was incubated
with 106 cells in 0.5 ml of culture medium for 0, 4, 8, 12 or 24 h.
Data represent the mean ± s.d. of three experiments.
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Figure 2 Changed susceptibility of tumour cells to NK cells
following TNF-a treatment (100unitsml-') for 48h. U87-MG (0,-), K562 (A,A) or ACHN (V,V) cells were untreated (0,
A, V) or treated (0, A, V) with TNF-a. The assays were
performed with an incubation time of 4 h. 0-0 versus 0*,
P<0.1; A-A versus A-A, P<0.05; V-V versus V-V, results
not significant. Data represent the mean ± s.d. of three
experiments.
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Figure 4 Immunofluorescence analysis of ICAM-1 (I and 3) and
HLA class I antigen (2 and 4) on U87-MG ( ), K562 ( ---) or
ACHN ( ) cells without (I and 2) or with TNF-a treatment
(100 units ml-') (3, 4) for 48h.
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Figure 5 Immunofluorescence analysis of (a) ICAM-1 and (b)
HLA class I antigen on U87-MG cells with or without TNF-a
treatment (100 units ml-') for 48 h. ----, negative control. (1),
untreated U87-MG cells; (2), TNF-a-treated U87-MG cells; (3),
combined TNF-a- and antisense-ICAM-1-treated U87-MG cells;
(4), combined TNF-a- and acid-treated U87-MG cells.
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Figure 6 Effect of ICAM-1 and HLA class I antigen on lysis by
NK cells of U87-MG cells treated with TNF-a (100 units ml -')
for 48 h. Cytotoxicity assay was performed without treatment
(0), with antisense-ICAM- 1 treatment alone (V), with acid
treatment alone (V), with TNF-a treatment alone (@), with
combined TNF-a and antisense ICAM-1 treatment (A) or with
combined TNF-m and acid treatment (A). 0-0) versus (@-0),
P<0.1; *-0 versus A-A, P<0.05; V-V versus A-A,
P<0.1; A-A versus *0-, P<0.05; A-A versus V-V,
P <0.05. Data represent the mean ± s.d. of three experiments.
E/T ratios of 20 and 40 (P<0.05). In addition, the combined
treatment with TNF-a and antisense ICAM-1 decreased
susceptibility to NK lysis of U87-MG cells compared with
antisense ICAM-1 treatment alone (P<0.1). On the other
hand, TNF-a-treated U87-MG cells had greatly increased
susceptibility to lysis by NK cells after acid treatment at all
E/T ratios tested (P<0.05). Moreover, the combined treat-
ment with TNF-a and acid increased susceptibility to NK
lysis of U87-MG cells compared with acid treatment alone
(P<0.05). These results suggest the possibility that the in-
creased NK susceptibility of TNF-x-treated U87-MG cells
mostly depends on the increased expression of ICAM-1 on
target cells, whereas HLA class I antigen expression has a
protective effect. Similar results were obtained with GI-1 cells
(derived from human malignant glioma cells, Miyatake et al.,
1990; Kondo et al., 1992).
Discussion
It has been proposed that HLA antigens are regulators of
tumour cell susceptibility to immune cytolysis, and lack of
HLA class I antigen has generally been found to be associ-
ated with increased susceptibility to lysis by NK cells
(Tanaka et al., 1986; Weber et al., 1987; Ljunggren & Karre,
1990). However, in some studies no significant change has
been detected in the extent of NK-cell-mediated lysis when
HLA class I antigen expression is below a threshold level or
above a plateau level (Storkus et al., 1989). On the other
hand, it has been found that some adhesion factors, such as
ICAM-1, and extracellular matrix proteins such as laminin,
collagen IV and fibronectin can activate cytolytic immunity
effectors through the lymphocyte function-associated antigen
(LFA) and very late antigen (VLA) receptor system (Young,
1989; Takahashi et al., 1990; Santoni et al., 1991). Further-
more, several non-specific properties of tumour cells have
been implicated in the susceptibility of such cells to lysis by
NK cells. Cell-surface hydrophobicity (Becker et al., 1979),
sialic acid composition (Yogeeswaran et al., 1981), glyco-
protein composition (Young et al., 1981), cell membrane
repair mechanisms (Kunkel & Welsh, 1981) and cell mem-
brane potential (Stevenson et al., 1989) have all been
reported to affect cytolysis by NK cells. The mechanism
responsible for NK-cell-mediated lysis of target cells remains
to be determined.
It has recently been reported that the expression of ICAM-
I and HLA class I antigen on glioma cell lines can be
significantly enhanced by interferon (IFN)-y or TNF-o (Kup-
pner et al., 1990; Miyatake et al., 1990). The non-HLA-NK
cytolysis-related structures are also more susceptible to
modulation by TNF-a than by IFN-'y (Maio et al., 1991). We
therefore studied both the effect of TNF-x treatment of
glioblastoma cells on susceptibility to lysis by NK cells and
the expression of ICAM-1 and HLA class I antigen before
and after TNF-o treatment. Our findings demonstrated that
TNF-a treatment induced the expression of ICAM-1 to
higher levels than that of HLA class I antigen on U87-MG
cells and increased NK susceptibility, while NK-sensitive
K562 cells showed a higher increase in HLA class I antigen
than of ICAM-1 and decreased NK susceptibility after TNF-
a treatment. On the other hand, the expression of ICAM-1
and HLA class I antigen on NK-resistant ACHN cells was
slightly augmented to the same extent and NK susceptibility
was not changed after TNF-oc treatment. Therefore, we sug-
gest that the increase in susceptibility of tumour cells to NK
lysis may mainly correlate with up-regulation of ICAM-l and
the decrease with up-regulation of HLA class I antigen.
Furthermore, in order to determine in more detail whether
the increased susceptibility to lysis by NK cells was a conse-
quence of the increased expression of ICAM-1 and HLA
class I antigen on TNF-x-treated U87-MG cells, we
eliminated one or the other of these two cell-surface
molecules with the use of antisense ICAM-1 or acid treat-
ment. We used the ICAM-1 antisense oligonucleotide to
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ICAM-l antibody, since use of the whole IgG of the anti-
ICAM-l antibody may induce an antibody-dependent cell-
mediated cytotoxicity (ADCC) reaction (Maio et al., 1991).
The ability of a MAb to detect antigenic determinants may
be somewhat decreased with the use of F(ab')2 fragments
prepared by-pepsin digestion: the MAb is capable of blocking
cell-mediated cytotoxicity but does not eliminate ICAM-1
from the cell surface, and there may also be differences in
characteristics of the MAb tested and in the antigenic profiles
of the cells. Acid treatment resulted in the elimination of
HLA class I antigen expression, but did not affect the expres-
sion of ICAM-1, NCAM, HLA class II or other similar
cell-surface antigens, confirming the findings of Sugawara et
al. (1989). However, there has been no report demonstrating
whether non-specific properties such as cell membrane poten-
tial remain unchanged after acid treatment. We suggest that
acid treatment has no effect on these non-specific properties
since K562 cells expressing no or very low HLA class I
antigen showed the same susceptibility to NK lysis before
and after acid treatment (Sugawara et al., 1989).
We also showed that antisense ICAM-1 induced significant
inhibition of NK-cell-mediated lysis of TNF-a-treated U87-
MG cells. Acid treatment following TNF-a treatment also
greatly increased lysis by NK cells. These findings indicate
that TNF-o treatment of glioblastoma cells increased their
susceptibility to lysis by NK cells, since ICAM-1 up-
regulation would have more profound effects on NK suscep-
tibility than would HLA class I antigen up-regulation.
Treatments with TNF-a or IFN-y have in a variety of
studies increased, decreased or left unchanged the suscep-
tibility of tumour cells to lysis by NK/lymphokine-activated
killer (LAK) cells (Miyatake et al., 1990; Maio et al., 1991;
Akella & Hall, 1992; Fady et al., 1992; Kondo et al., 1992).
One possible explanation for the inconsistencies among these
findings would be the existence of differences not only in the
levels of ICAM-1 and HLA class I antigen but also in the
susceptibility to lysis by NK/LAK cells of cells not treated
with cytokines (Fady et al., 1992). A NK/LAK-resistant
target cell with a high level of expression of HLA class I
antigen but a low level of expression of ICAM-1 would be
more likely to respond to cytokines with enhanced suscep-
tibility to lysis.
Moreover, since TNF-x plays a role in immune defence
against a variety of pathogenic agents by virtue of its posses-
sion of a variety of effects on cell function (Beutler &
Cerami, 1987; Old, 1987; Konig et al., 1991), it is possible
that an unknown molecule, neither ICAM-1 nor HLA class I
antigen, might be responsible for susceptibility to lysis by
NK cells. Several groups have shown that marked inhibition
of NK-mediated cytolysis is induced by anti-LFA-1-e
(CDlla) and anti-LFA-l-,B (CD18) MAbs; these findings
strongly suggest such surface molecules play important roles
in NK-mediated cytolysis (Hall et al., 1985; Schmidt et al.,
1985). In addition, it has been found that ICAM-1 appears
to be constitutively avid for LFA-1. In contrast, cell-surface
LFA-1 is not constitutively avid for ICAM-1 (Dustin &
Springer, 1988). The findings of these studies suggest that
LFA-1 ligands other than ICAM-1 may be present on NK
targets. Another possible explanation is that the intrinsic
ability of the target cells to be lysed might be altered by
TNF-a. However, further studies are needed to determine
clearly the mechanism of NK-mediated lysis.
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